If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]
▪ Publication online of the mechanism of action of HERV-K ENV in sporadic amyotrophic lateral sclerosis (ALS), resulting in motor neuron death
▪ This publication confirms the preclinical therapeutic effect of GeNeuro’s anti-HERV-K ENV antibody to neutralize the toxicity of HERV-K ENV
▪ Sporadic ALS is a devastating disease affecting 10,000 new patients per year in the United States and Europe, associated with a limited survival prognosis
GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID- 19 (post-COVID), today announces the publication in the leading scientific journal “Annals of Neurology” of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS). NINDS is part of the US National Institutes of Health (NIH). This publication describes the new pathogenic mechanism of HERV-K in sporadic ALS and confirms the action of the GeNeuro antibody to neutralize this toxicity.